Cell Therapies, Redefined

Pervasis’ therapies harness the power of the endothelium, which has a well-understood role in regulating many of the body’s healing processes, including vascular repair.

Our next-generation approach is designed to overcome the clinical and commercial challenges that have limited the growth of cell-based therapies to date. Key elements of our approach include the following:

• Fully differentiated adult cells: Unlike other approaches, which work to “coax” progenitor cells into a differentiated state, we use fully differentiated endothelial cells, and their role in effecting vascular repair is well-understood.
• Allogeneic cells: Unlike autologous cell-based therapies, our products will be available “off-the-shelf” when needed, thus overcoming a major barrier to commercial adoption.
• Three-dimensional matrix: Our therapies are embedded in a well-characterized polymer matrix, which acts as an anchor for the endothelial cells and enables them to exert their full biological activity.
• Immune-privileged formulation: Proof of concept clinical trials for our treatments demonstrate clear safety and immune system tolerance, providing a strong rationale for a broad off-the-shelf platform.
• Targeted delivery, localized effect: Our therapies are placed on the outside of the vessel at the site of vascular intervention, initiating a highly localized set of biochemical signals until being safely resorbed into the body after four to eight weeks.
• Acute care, lasting effect: Preclinical and clinical studies suggest that a single administration of our treatments have the potential to regulate healing in the acute setting in conjunction with vascular procedures and may provide a positive, long-term effect in patients up to two years following a vascular procedure.